Skip to main content
Carisma Therapeutics Inc. logo

Carisma Therapeutics Inc. — Investor Relations & Filings

Ticker · CARM ISIN · US14216R1014 LEI · 549300DGKHONOZQIY116 US Manufacturing
Open in API
Filings indexed 853 across all filing types
Latest filing 2025-07-15 Regulatory Filings
Country US United States of America
Listing US CARM

About Carisma Therapeutics Inc.

https://sesenbio.com/

Carisma Therapeutics Inc. is a clinical-stage biotechnology company pioneering the development of engineered macrophage-based therapeutics. The company's proprietary cell therapy platform is centered on Chimeric Antigen Receptor Macrophages (CAR-M) and CAR-Monocytes. This approach is designed to leverage the unique abilities of macrophages to infiltrate solid tumors, overcome the immunosuppressive tumor microenvironment, and stimulate a broad anti-tumor response. Carisma's pipeline is focused on developing treatments for cancer and other serious disorders, including fibrosis.

Recent filings

Filing Released Lang Actions
425 Filing
Regulatory Filings
2025-07-15 English
DEF 14A
Proxy Solicitation & Information Statement
2025-07-07 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, specifically a Preliminary Proxy Statement for a Special Meeting of Stockholders. It includes detailed information about proposals to be voted on, including a reverse stock split and adjournment proposal, instructions for voting, and background on Nasdaq listing compliance issues. The document is not a full financial report, earnings release, or management discussion, but rather materials sent to shareholders to provide information and solicit votes for a meeting. This matches the definition of a Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is the proxy statement itself, not just an announcement of its availability.
2025-06-27 English
425 Filing
Regulatory Filings
2025-06-25 English
FORM 8-K
M&A Activity Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 22, 2025, by Carisma Therapeutics Inc. The content focuses on the announcement of a Merger Agreement between Carisma and OrthoCellix, detailing the terms of the merger, contingent value rights, concurrent investment, support agreements, and lock-up agreements. The document is an announcement of a significant corporate transaction (merger) and includes detailed descriptions of the merger terms and related agreements. It is not a full merger proxy statement or tender offer filing (which would be classified under MA or TAR), but rather a current report announcing the merger agreement and related material definitive agreements. Therefore, the most appropriate classification is M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2025-06-23 English
425 Filing
Regulatory Filings
2025-06-23 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.